Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Down 73.7% in January

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large decrease in short interest in the month of January. As of January 30th, there was short interest totaling 1,434 shares, a decrease of 73.7% from the January 15th total of 5,444 shares. Based on an average trading volume of 25,027 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 25,027 shares, the short-interest ratio is currently 0.1 days.

Barinthus Biotherapeutics Stock Down 5.4%

NASDAQ BRNS opened at $0.63 on Friday. The company has a 50-day moving average price of $0.72 and a 200-day moving average price of $1.01. Barinthus Biotherapeutics has a 52 week low of $0.56 and a 52 week high of $2.92. The firm has a market capitalization of $25.54 million, a P/E ratio of -0.33 and a beta of -0.66.

Hedge Funds Weigh In On Barinthus Biotherapeutics

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Baird Financial Group Inc. boosted its stake in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 192,461 shares of the company’s stock after acquiring an additional 100,000 shares during the period. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. HC Wainwright raised their target price on shares of Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research report on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Barinthus Biotherapeutics has a consensus rating of “Hold” and an average target price of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.